In Vitro antibacterial activities of JNJ-Q2, a new broad-spectrum fluoroquinolone

Antimicrobial Agents and Chemotherapy

Volumn 54, Issue 5, 2010, Pages 1955-1964

  Morrow, Brian J ^a   He, Wenping ^a   Amsler, Karen M ^a   Foleno, Barbara D ^a   Macielag, Mark J ^a   Lynch, A Simon ^a   Bush, Karen ^b  

^a JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

^b INDIANA UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZALKONIUM CHLORIDE; CIPROFLOXACIN; DNA TOPOISOMERASE; DNA TOPOISOMERASE (ATP HYDROLYSING) A; ERYTHROMYCIN; ETHIDIUM BROMIDE; GEMIFLOXACIN; JNJ Q2; LEVOFLOXACIN; LINEZOLID; MOXIFLOXACIN; PENICILLIN G; PROTEIN PARC; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RESERPINE; UNCLASSIFIED DRUG; VANCOMYCIN;

AGAR DILUTION; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; BROTH DILUTION; CITROBACTER FREUNDII; COMPARATIVE STUDY; ENTEROBACTER AEROGENES; ENTEROBACTER CLOACAE; ENTEROCOCCUS FAECALIS; ENTEROCOCCUS FAECIUM; ESCHERICHIA COLI; HAEMOPHILUS INFLUENZAE; IN VITRO STUDY; KLEBSIELLA PNEUMONIAE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MORAXELLA CATARRHALIS; MUTATION; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEUS MIRABILIS; PROVIDENCIA STUARTII; PSEUDOMONAS AERUGINOSA; RESPIRATORY SYSTEM; SERRATIA MARCESCENS; SKIN; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS AGALACTIAE; STREPTOCOCCUS GROUP C; STREPTOCOCCUS PNEUMONIAE; STREPTOCOCCUS PYOGENES;

ANTI-BACTERIAL AGENTS; CIPROFLOXACIN; DRUG DESIGN; DRUG RESISTANCE, BACTERIAL; ESCHERICHIA COLI; FLUOROQUINOLONES; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE;

EID: 77951247938     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01374-09     Document Type: Article

References (45)

1. Adam, H. J., D. J. Hoban, A. S. Gin, and G. G. Zhanel. 2009. Association between fluoroquinolone usage and a dramatic rise in ciprofloxacin-resistant Streptococcus pneumoniae in Canada, 1997-2006. Int. J. Antimicrob. Agents 34:82-85.
2. Almer, L. S., J. B. Hoffrage, E. L. Keller, R. K. Flamm, and V. D. Shortridge. 2004. In vitro and bactericidal activities of ABT-492, a novel fluoroquinolone, against gram-positive and gram-negative organisms. Antimicrob. Agents Chemother. 48:2771-2777.
3. Anderegg, T. R., and R. N. Jones. 2004. Bactericidal activity of garenoxacin tested by kill-curve methodology against wild type and QRDR mutant strains of Streptococcus pneumoniae. Diagn. Microbiol. Infect. Dis. 50:213-217.
4. Ardanuy, C., D. Rolo, A. Fenoll, D. Tarrago, L. Calatayud, and J. Liñares. 2009. Emergence of a multidrug-resistant clone (ST320) among invasive serotype 19A pneumococci in Spain. J. Antimicrob. Chemother. 64:507-510.
5. Bhagwat, S. S., P. McGhee, K. Kosowska-Shick, M. V. Patel, and P. C. Appelbaum. 2009. In vitro activity of the quinolone WCK 771 against recent U.S. hospital and community-acquired Staphylococcus aureus pathogens with various resistance types. Antimicrob. Agents Chemother. 53:811-813.
6. Bhagwat, S. S., L. A. Mundkur, S. V. Gupte, M. V. Patel, and H. F. Khorakiwala. 2006. The anti-methicillin-resistant Staphylococcus aureus quinolone WCK 771 has potent activity against sequentially selected mutants, has a narrow mutant selection window against quinolone-resistant Staphylococcus aureus, and preferentially targets DNA gyrase. Antimicrob. Agents Chemother. 50:3568-3579.
7. Bisognano, C., P. Vaudaux, P. Rohner, D. P. Lew, and D. C. Hooper. 2000. Induction of fibronectin-binding proteins and increased adhesion of quinolone-resistant Staphylococcus aureus by subinhibitory levels of ciprofloxacin. Antimicrob. Agents Chemother. 44:1428-1437.
8. Blumberg, H. M., D. Rimland, D. J. Carroll, P. Terry, and I. K. Wachsmuth. 1991. Rapid development of ciprofloxacin resistance in methicillin-susceptible and -resistant Staphylococcus aureus. J. Infect. Dis. 163:1279-1285.
9. Clark, C., K. Smith, L. Ednie, T. Bogdanovich, B. Dewasse, P. McGhee, and P. C. Appelbaum. 2008. In vitro activity of DC-159a, a new broad-spectrum fluoroquinolone, compared with that of other agents against drug-susceptible and -resistant pneumococci. Antimicrob. Agents Chemother. 52:77-84.
10. CLSI. 2009. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard, 8th ed. CLSI document M07-A8, vol. 29, no. 2. CLSI, Wayne, PA.
11. CLSI. 2009. Performance standards for antimicrobial susceptibility testing; 19th informational supplement. CLSI document M100-S19, vol. 29, no. 3. CLSI, Wayne, PA.
12. Crane, G. J., S. M. Thomas, and M. E. Jones. 1996. A modified Luria-Delbruck fluctuation assay for estimating and comparing mutation rates. Mutat. Res. 354:171-182.
13. Dagan, R., N. Givon-Lavi, E. Leibovitz, D. Greenberg, and N. Porat. 2009. Introduction and proliferation of multidrug-resistant Streptococcus pneumoniae serotype 19A clones that cause acute otitis media in an unvaccinated population. J. Infect. Dis. 199:776-785.
14. Davies, T. A., R. Goldschmidt, S. Pfleger, M. Loeloff, K. Bush, D. F. Sahm, and A. Evangelista. 2003. Cross-resistance, relatedness and allele analysis of fluoroquinolone-resistant US clinical isolates of Streptococcus pneumoniae (1998-2000). J. Antimicrob. Chemother. 52:168-175.
15. Davies, T. A., Y. C. Yee, K. Amsler, R. Goldschmidt, D. F. Sahm, and A. T. Evangelista. 2008. Sporadic occurrences of fluoroquinolone-resistant Streptococcus pneumoniae in the United States: longitudinal analysis of institutions from the New England and West South Central regions during the TRUST 4-9 (2000-2005) surveillance studies. Postgrad. Med. 120:25-31.
16. Davies, T. A., Y. C. Yee, K. Bush, D. Sahm, A. Evangelista, and R. Goldschmidt. 2008. Effects of the 7-valent pneumococcal conjugate vaccine on U.S. levofloxacin-resistant Streptococcus pneumoniae. Microb. Drug Resist. 14:187-196.
17. Davies, T. A., Y. C. Yee, R. Goldschmidt, D. F. Sahm, and A. T. Evangelista. 2008. Decline in the prevalence of pandemic clones Spain23F-1 and Spain9V-3 among US fluoroquinolone-resistant Streptococcus pneumoniae TRUST surveillance isolates since 2001. Postgrad. Med. 120:39-45.
18. de la Campa, A. G., C. Ardanuy, L. Balsalobre, E. Perez-Trallero, J. M. Marimon, A. Fenoll, and J. Linares. 2009. Changes in fluoroquinoloneresistant Streptococcus pneumoniae after 7-valent conjugate vaccination, Spain. Emerg. Infect. Dis. 15:905-911.
19. Draghi, D. C., M. E. Jones, D. F. Sahm, and G. S. Tillotson. 2006. Geographically-based evaluation of multidrug resistance trends among Streptococcus pneumoniae in the USA: findings of the FAST surveillance initiative (2003-2004). Int. J. Antimicrob. Agents 28:525-531.
20. Drlica, K., and M. Malik. 2003. Fluoroquinolones: action and resistance. Curr. Top. Med. Chem. 3:249-282.
21. Drlica, K., and X. Zhao. 2007. Mutant selection window hypothesis updated. Clin. Infect. Dis. 44:681-688.
22. File, T. 2009. The science of selecting antimicrobials for community-acquired pneumonia (CAP). J. Manag. Care Pharm. 2(Suppl.):S5-S11.
23. Firsov, A. A., S. N. Vostrov, I. Y. Lubenko, K. Drlica, Y. A. Portnoy, and S. H. Zinner. 2003. In vitro pharmacodynamic evaluation of the mutant selection window hypothesis using four fluoroquinolones against Staphylococcus aureus. Antimicrob. Agents Chemother. 47:1604-1613.
24. Foleno, B., B. J. Morrow, E. Wira, M. Macielag, and K. Bush. 2008. Broad spectrum in vitro activity of JNJ-Q2, a new fluoroquinolone, abstr. F1-2033. Abstr. 48th Annu. Intersci. Conf. Antimicrob. Agents Chemother. (ICAAC)-Infect. Dis. Soc. Am. (IDSA) 46th Annu. Meet. American Society for Microbiology and Infectious Diseases Society of America, Washington, DC.
25. Fritsche, T. R., H. S. Sader, and R. N. Jones. 2007. Potency and spectrum of garenoxacin tested against an international collection of skin and soft tissue infection pathogens: report from the SENTRY antimicrobial surveillance program (1999-2004). Diagn. Microbiol. Infect. Dis. 58:19-26.
26. Fuller, J. D., and D. E. Low. 2005. A review of Streptococcus pneumoniae infection treatment failures associated with fluoroquinolone resistance. Clin. Infect. Dis. 41:118-121.
27. He, W., K. Amsler, K. Bush, and B. J. Morrow. 2008. In vitro Staphylococcus aureus activities and resistance selection in MRSA with the new fluoroquinolone JNJ-Q2, p. F1-2035. Abstr. 48th Annu. Intersci. Conf. Antimicrob. Agents Chemother. (ICAAC)-Infect. Dis. Soc. Am. (IDSA) 46th Annu. Meet. American Society for Microbiology and Infectious Diseases Society of America, Washington, DC.
28. Hookey, J. V., V. Edwards, B. D. Cookson, and J. F. Richardson. 1999. PCR-RFLP analysis of the coagulase gene of Staphylococcus aureus: application to the differentiation of epidemic and sporadic methicillin-resistant strains. J. Hosp. Infect. 42:205-212.
29. Hoshino, K., K. Inoue, Y. Murakami, Y. Kurosaka, K. Namba, Y. Kashimoto, S. Uoyama, R. Okumura, S. Higuchi, and T. Otani. 2008. In vitro and in vivo antibacterial activities of DC-159a, a new fluoroquinolone. Antimicrob. Agents Chemother. 52:65-76.
30. Jones, M. E., S. M. Thomas, and A. Rogers. 1994. Luria-Delbruck fluctuation experiments: design and analysis. Genetics 136:1209-1216.
31. Jones, R. N., T. R. Fritsche, and H. S. Sader. 2008. Antimicrobial activity of DC-159a, a new fluoroquinolone, against 1,149 recently collected clinical isolates. Antimicrob. Agents Chemother. 52:3763-3775.
32. Jones, R. N., T. R. Fritsche, H. S. Sader, and M. G. Stilwell. 2007. Activity of garenoxacin, an investigational des-F(6)-quinolone, tested against pathogens from community-acquired respiratory tract infections, including those with elevated or resistant-level fluoroquinolone MIC values. Diagn. Microbiol. Infect. Dis. 58:9-17.
33. Jones, R. N., H. S. Sader, M. G. Stilwell, and T. R. Fritsche. 2007. Garenoxacin activity against isolates form patients hospitalized with community-acquired pneumonia and multidrug-resistant Streptococcus pneumoniae. Diagn. Microbiol. Infect. Dis. 58:1-7.
34. Kaatz, G. W., V. V. Moudgal, and S. M. Seo. 2002. Identification and characterization of a novel efflux-related multidrug resistance phenotype in Staphylococcus aureus. J. Antimicrob. Chemother. 50:833-838.
35. Kays, M. B., G. G. Zhanel, M. A. Reimann, J. Jacobi, G. A. Denys, D. W. Smith, and M. F. Wack. 2007. Selection of a gyrA mutation and treatment failure with gatifloxacin in a patient with Streptococcus pneumoniae with a preexisting parC mutation. Pharmacotherapy 27:221-226.
36. Korzheva, N., T. A. Davies, and R. Goldschmidt. 2005. Novel Ser79Leu and Ser81Ile substitutions in the quinolone resistance-determining regions of ParC topoisomerase IV and GyrA DNA gyrase subunits from recent fluoroquinolone- resistant Streptococcus pneumoniae clinical isolates. Antimicrob. Agents Chemother. 49:2479-2486.
37. Korzheva, N., T. A. Davies, and R. Goldschmidt. 2005. Susceptibilities to fluoroquinolones and incidences of various Ser79 ParC and Ser81 GyrA amino acid substitutions among Streptococcus pneumoniae, abstr. C1-1041. Abstr. 45th Annu. Intersci. Conf. Antimicrob. Agents Chemother. (ICAAC), Washington, DC.
38. Morrow, B. J., B. Foleno, R. Goldschmidt, W. He, K. Amsler, M. Macielag, and K. Bush. 2008. In vitro activity of JNJ-Q2, a new fluoroquinolone, against susceptible and multi-drug resistant Streptococcus pneumoniae, F1-2052. Abstr. 48th Anni. Intersci. Conf. Antimicrob. Agents Chemother. (ICAAC)-Infect. Dis. Soc. Am. (IDSA) 46th Annu. Meet. American Society for Microbiology and Infectious Diseases Society of America, Washington, DC.
39. Nakanishi, N., S. Yoshida, H. Wakebe, M. Inoue, T. Yamaguchi, and S. Mitsuhashi. 1991. Mechanisms of clinical resistance to fluoroquinolones in Staphylococcus aureus. Antimicrob. Agents Chemother. 35:2562-2567.
40. Nikaido, H. 2009. Multidrug resistance in bacteria. Annu. Rev. Biochem. 78:119-146.
41. Schmitz, F. J., A. C. Fluit, M. Luckefahr, B. Engler, B. Hofmann, J. Verhoef, H. P. Heinz, U. Hadding, and M. E. Jones. 1998. The effect of reserpine, an inhibitor of multidrug efflux pumps, on the in-vitro activities of ciprofloxacin, sparfloxacin and moxifloxacin against clinical isolates of Staphylococcus aureus. J. Antimicrob. Chemother. 42:807-810.
42. Schmitz, F. J., M. E. Jones, B. Hofmann, B. Hansen, S. Scheuring, M. Luckefahr, A. Fluit, J. Verhoef, U. Hadding, H. P. Heinz, and K. Kohrer. 1998. Characterization of grlA, grlB, gyrA, and gyrB mutations in 116 unrelated isolates of Staphylococcus aureus and effects of mutations on cipro-floxacin MIC. Antimicrob. Agents Chemother. 42:1249-1252.
43. Song, J.-H., S.-I. Jung, K. S. Ko, N. Y. Kim, J. S. Son, H.-H. Chang, H. K. Ki, W. S. Oh, J. Y. Suh, K. R. Peck, N. Y. Lee, Y. Yang, Q. Lu, A. Chongthaleong, C.-H. Chiu, M. K. Lalitha, J. Perera, T. T. Yee, G. Kumarasinghe, F. Jamal, A. Kamarulzaman, N. Parasakthi, P. H. Van, C. Carlos, T. So, T. K. Ng, and A. Shibl. 2004. High prevalence of antimicrobial resistance among clinical Streptococcus pneumoniae isolates in Asia (an ANSORP study). Antimicrob. Agents Chemother. 48:2101-2107.
44. Takenouchi, T., F. Tabata, Y. Iwata, H. Hanzawa, M. Sugawara, and S. Ohya. 1996. Hydrophilicity of quinolones is not an exclusive factor for decreased activity in efflux-mediated resistant mutants of Staphylococcus aureus. Antimicrob. Agents Chemother. 40:1835-1842.
45. Watanabe, S., T. Ito, and K. Hiramatsu. 2007. Susceptibilities of healthcare- and community-associated methicillin-resistant staphylococci to the novel des-F(6)-quinolone DX-619. J. Antimicrob. Chemother. 60:1384-1387.